L’étude montre que la Mélatonine a des effets contre la sarcopénie



La sarcopénie est un syndrome gériatrique se caractérisant dans un premier temps par une diminution de la masse musculaire qui en s’aggravant sera à l’origine d’une détérioration de la force musculaire et des performances physiques. Le terme « sarcopénie » a initialement été défini par Irwen Rosenberg (Senior Scientist Jean Mayer SDA HNRCA Tufts University Boston, MA) en 1988 pour désigner la diminution de la masse squelettique au cours du vieillissement. La sarcopénie observée chez la personne âgée est imputable au processus de vieillissement mais peut être accélérée par des facteurs pathologiques et comportementaux tels que la dénutrition et la sédentarité. L´étude dans PubMed montre que la Mélatonine a des effets contre la sarcopénie.


Melatonin as a Potential Agent in the Treatment of Sarcopenia.
Int J Mol Sci. 2016 Oct 24;17(10): - Authors: Coto-Montes A, Boga JA, Tan DX, Reiter RJ
https://www.ncbi.nlm.nih.gov/pubmed/27783055?dopt=Abstract


Int J Mol Sci. 2016 Oct 24;17(10):

Authors: Coto-Montes A, Boga JA, Tan DX, Reiter RJ

Abstract
Considering the increased speed at which the world population is aging, sarcopenia could become an epidemic in this century. This condition currently has no means of prevention or treatment. Melatonin is a highly effective and ubiquitously acting antioxidant and free radical scavenger that is normally produced in all organisms. This molecule has been implicated in a huge number of biological processes, from anticonvulsant properties in children to protective effects on the lung in chronic obstructive pulmonary disease. In this review, we summarize the data which suggest that melatonin ( mélatonine )may be beneficial in attenuating, reducing or preventing each of the symptoms that characterize sarcopenia. The findings are not limited to sarcopenia, but also apply to osteoporosis-related sarcopenia and to age-related neuromuscular junction dysfunction. Since melatonin ( mélatonine )has a high safety profile and is drastically reduced in advanced age, its potential utility in the treatment of sarcopenic patients and related dysfunctions should be considered.

PMID: 27783055 [PubMed - in process]
https://www.ncbi.nlm.nih.gov/pubmed/27783055?dopt=Abstract

Melatonine - Multilenguages section Key Melatonin